'New Visiongain Report Shows Commercial Prospects for the 20 Leading Biopharmaceutical Companies' Says Recent Visiongain Study

English
5 Pages
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

'New Visiongain Report Shows Commercial Prospects for the 20 Leading Biopharmaceutical Companies' Says Recent Visiongain Study PR Newswire LONDON, September 11, 2012 LONDON, September 11, 2012 /PRNewswire/ -- A new report by visiongain assesses prospects for the leading 20 biopharma companies worldwide. Top pharmaceutical companies have consolidated their hold on the market by buying up most of the leading biotech products and platforms, according to Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022, published in September 2012. Visiongain's study predicts revenues to 2022 for the leading companies and discusses their prospects. Roche continues to lead the market via its Genentech-developed biologics portfolio, but other multinationals are following. Top 10 players, according to the report's analysis, include Sanofi, which acquired Genzyme, GlaxoSmithKline, which this summer completed a takeover of Human Genome Sciences, and Pfizer, which bought Wyeth in 2009 to expand its capacities in vaccines and biologics. Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "The pharmaceutical industry is continuing to absorb the healthcare biotech industry. Amgen is still an independent biotech, but it is diversifying into generics, so the distinction between the two types of companies is being eroded from both sides.

Subjects

Informations

Published by
Reads 12
Language English
Report a problem
'New Visiongain Report Shows Commercial Prospects for the 20 Leading Biopharmaceutical Companies' Says Recent Visiongain Study
PR Newswire LONDON, September 11, 2012
LONDON,September 11, 2012/PRNewswire/ --A new report by visiongain assesses prospects for the leading 20 biopharma companies worldwide. Top pharmaceutical companies have consolidated their hold on the market by buying up most of the leading biotech products and platforms, according to Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022, published inSeptember 2012. Visiongain's study predicts revenues to 2022 for the leading companies and discusses their prospects. Roche continues to lead the market via its Genentech-developed biologics portfolio, but other multinationals are following. Top 10 players, according to the report's analysis, include Sanofi, which acquired Genzyme, GlaxoSmithKline, which this summer completed a takeover of Human Genome Sciences, and Pfizer, which bought Wyeth in 2009 to expand its capacities in vaccines and biologics. Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "The pharmaceutical industry is continuing to absorb the healthcare biotech industry. Amgen is still an independent biotech, but it is diversifying into generics, so the distinction between the two types of companies is being eroded from both sides. With biologics set to be the first, second and third bestselling pharmaceuticals of 2012, the competition for the biologics market is intense, and the coming of biosimilars is going to make it fiercer, by lowering the entry barriers for developing a biological drug. "The biologics market is growing faster than the broader pharmaceutical market, and growth rates will be sustained through to 2022, our analyses show. Newer biological formats such as antibody-drug conjugates, therapeutic vaccines and cellular therapies will compensate for slowdown and contraction in areas such as erythropoietin and interferons. There will be hot competition in insulins, recombinant coagulating factors and mAbs, as companies battle for these lucrative market areas." That new report forecasts that the biologics market will continue to expand rapidly to 2022, with leading pharma companies increasingly basing their growth strategies on opportunities in the biologics sector. Visiongain is a business information provider based inLondon, UK. Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 adds to that company's range of analytical reports on industries and markets in healthcare. For sample pages and further information concerning the visiongain report Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 please visit http://www.visiongain.com/Report/889/Pharma-Leader-Series-Top-20-Biological-Drug-Manufacturers-2012-2022
For an executive summary of this report please email: Sara Peerun at sara.peerun@visiongainglobal.com Tel: +44(0)20-7336-6100 Notes for Editors Companies listed in this report include: Abbott Laboratories Abgenix Ablynx AC Immune Acadia Pharmaceuticals Acorda Therapeutics Alantos Pharmaceuticals ALK Abello Allergan Alnara Pharmaceuticals Amgen AstraZeneca Avidia Baxter International Bayer HealthCare Becton Dickinson Biogen Idec Bioheart Biomira BioVex Boehringer Ingelheim Bristol-Myers Squibb (BMS) Cambridge Antibody Technologies Centocor Ortho Biotech Chinese Academy of Medical Sciences Chinese Academy of Sciences Chiron Cilag Chemie Coley Pharmaceuticals Corixa Cougar Biotechnology CovX Crucell Biotechnology CSL Behring CSL Biotherapies CT Arztneimittel Cytori Dompé Duke University Dyax Dynavax Eisai Elan Eli Lilly EMD Serono Encysive Pharmaceuticals
ExonHit Therapeutics Facet Biotech Fresenius F-Star Galena Biopharma Genentech Genesis Pharma Genetics Institute Genmab Genzyme GlaxoSmithKline GlycoFi Grifols GTC Biotherapeutics HD Biosciences Hexal Hoechst Marion Roussel Hospira HudsonAlpha Institute for Biotechnology Human Genome Sciences Hutchison MediPharma ID Biomedical Ilypsa ImClone Immunex Corporation ImmunoGen Inspire Pharmaceuticals Institute for Genomic Research International Vaccine Institute Ipsen Janssen Pharmaceutica Jiangsu Walvax Biotech Company Johns Hopkins University Johnson & Johnson KAI Pharmaceuticals Kinetix Pharmaceuticals King Knopp Neurosciences Kuros Kyorin Pharmaceutical Kyowa Hakko Kirin Lipoxen Ludwig Institute for Cancer Research McNeil Laboratories Medarex MedImmune Medixion Megapharm Merck & Co. Merck BioVentures Merck KGaA
Merck-Banyu Merz Pharma Micromet Millipore Mitsubishi Tanabe Pharma Molecular Partners MorphoSys Mustafa Nevzat Pharmaceuticals National Center for Drug Screening (China) Nestlé Neurimmune SubOne Novartis Novo Nordisk Oncothyreon Ortho Pharmaceutical Oxford University Pasteur Merieux Serums & Vaccins PDL BioPharma Peptech Pfizer Pharmacia Philogen Pieris Piramal Portola Pharmaceuticals PowderMed Protein Design Regeneron Roche Sabin Vaccine Institute Samsung Biologics Sandoz Sanofi Sanofi Pasteur MSD Sanwa Kagaku Kenkyusho Schering-Plough Senju Pharmaceutical Serenex Shanghai ChemExplorer Shanghai Institute of Biological Sciences Shanghai Institute of Materia Medica Shantha Biotechnics Sirna Therapeutics Solvay Pharmaceuticals Swedish Orphan Biovitrum Synergen Synovis Life Technologies Syntonix Takeda Talecris Teva Pharmaceutical Industries
Tianjin Medical University Cancer Hospital Transkaryotic Therapies Trellis Bioscience Trubion Tularik University of Queensland Upjohn Vaxdesign Vernalis VIVALis Walter Reed Army Institute Warner-Lambert World Health Organization (WHO) WuXi AppTec Wyeth Pharmaceuticals Zhejiang Taiyuan Zydus Cadila ZymoGenetics About visiongain Visiongain is one of the fastest growing and most innovative independent business intelligence companies inEurope. Based inLondon, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100